SEATTLE--(BUSINESS WIRE)--Bostwick Therapeutics announced today that it has received clearance from the U.S. Food and Drug Administration and the Institutional Review Board of Community Memorial Hospital, Ventura, CA., to initiate the CRITICAL (CRyotherapy and IntraTumoral Immunotherapy with immature dendritic Cells (AutoLogous)) trial, a clinical trial examining the potential of a novel combination of cryoablation and intra-tumoral injection of “virgin” dendritic cells (VDC2008) to treat men with metastatic androgen-independent prostate cancer. Cryoablation (freezing) of cancer in the prostate will employ state-of-the-art technology provided by Endocare, Inc., Irvine, CA.
